Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8161004 | 0.75 | ADK (0.44) | ADK | |
| SCHEMBL14636102 | 0.73 | NPC1 (0.36) | NPC1USP2TP53PKMRAB9A | |
| SCHEMBL13680688 | 0.60 | CCR1 (0.57) | NPC1USP2TP53PKMRAB9A | |
| SCHEMBL10348831 | 0.59 | NPC1 (1.00) | NPC1USP2TP53PKMRAB9A | |
| SCHEMBL5713283 | 0.58 | HTT (0.44) | — | |
| SCHEMBL27040551 | 0.56 | BACE1 (0.55) | NPC1USP2TP53PKMRAB9A | |
| SCHEMBL8319597 | 0.55 | IDO1 (0.50) | — | |
| SCHEMBL28667411 | 0.55 | IDO1 (0.50) | — | |
| SCHEMBL4278637 | 0.54 | NPC1 (0.58) | NPC1USP2TP53PKMRAB9A | |
| SCHEMBL3735138 | 0.54 | PTPN1 (0.70) | PTPN1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | ADK, AHCY, IAPP | NPC1 3466/4885USP2 1268/4885TP53 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.